Brief: Virpax Reports Favorable Preclinical Safety Data For Envelta

Virpax Pharmaceuticals

10/02/2022 14:21

Feb 10 (Reuters) - Virpax Pharmaceuticals Inc  VRPX.O :
    * VIRPAX REPORTS FAVORABLE PRECLINICAL SAFETY DATA FOR
ENVELTA™
 FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN
    * VIRPAX REPORTS FAVORABLE PRECLINICAL SAFETY DATA FOR
ENVELTA™
FOR TREATMENT OF ACUTE AND CHRONIC PAIN
    * VIRPAX PHARMACEUTICALS INC - PRECLINICAL STUDY DATA
INDICATE
THAT INTRANASAL ADMINISTRATION OF ENKEPHALIN (ENVELTA) IS
WELL-TOLERATED AND SAFE

Source text for Eikon:  ID:nBw3BW796a 
Further company coverage:  VRPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))